ADHDMAPNCT05518435
Managing Young People With ADHD in Primary Care Study
An observational study of ADHD, run by University of Exeter at 1 site in United Kingdom.
Trial summary
Background: Attention deficit hyperactivity disorder (ADHD) is the most common childhood neurodevelopmental disorder. It affects around 5% of children and adolescents, and up to 40% continue to experience symptoms into adulthood. Read more about this study
- Who is it for?
- Ages 16 years and olderHealthy volunteers can take part
- Conditions the study is for
- ADHD
- What is being tested?
- None, observational study
- How many people
- 816 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 28 Sep 2022to 31 Mar 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 years and older
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: WP1 SURVEY The sampling frame for WP1 includes all stakeholders aged 16 or over with an interest in providing or receiving health care for young people with ADHD, as well as those involved in providing/commissioning local primary care provision. WP2 QUALITATIVE STUDY The sampling frame for WP2 consists of a purposive selection of stakeholders. WP3 CO-PRODUCTION The sampling frame for WP3 consists of a purposive selection of key stakeholders. In addition to the key stakeholder groups outlined above, co-production activities will also involve MAP study researchers.
Who may be able to join
- Self-identifies as
- Being at least one of the following:
- A person aged 16 or over with lived experience of ADHD, or parent/carer of a person with ADHD
- Health professional (person working in any role that provides healthcare services, include NHS, voluntary and private services, clinical, managerial, leadership and administrative roles)
- Commissioner/provider of National Health Service (NHS) healthcare services (e.g., member of clinical commissioning group, primary care network (PCN), integrated care system (ICS), or another NHS organisation)
- Currently resident, working, or studying in England
Show all 19Show fewer
- One of the following:
- Young person aged 16-25 with lived experience of ADHD, or a parent/carer of a young person with ADHD
- Health professional (person that provides healthcare services with a focus on primary care, including clinical, managerial, leadership and administrative roles)
- Commissioner/provider of healthcare services (e.g., member of clinical commissioning group, PCN, ICS, NHS, or another organisation)
- Currently resident or working in England
- Currently resident or working close to one of the qualitative study sites identified following WP1, where 'close to' means located within the same geographic locality (to be decided based on findings from WP1)
- One of the following:
- Young person aged 16-25 with lived experience of ADHD, or a parent/carer of a young person with ADHD
- Health professional (person that provides healthcare services, including clinical, managerial, leadership and administrative roles)
- Commissioner/provider of NHS healthcare services (e.g., member of clinical commissioning group, PCN, ICS, local authority, or another NHS organisation)
- A member of the MAP study research team
- Currently resident, working, or studying in England
- Willing and able to work collaboratively and engage in consultations to co-produce evidence-based guidance for improving the co-ordination of primary care for young people with ADHD
Who cannot join
- Does not identify as a person aged 16 or over with lived experience of ADHD, a health professional, or a commissioner/provider of NHS health services
- Not currently resident, working, or studying in England
- WP2 QUALITATIVE STUDY
- Not a young person aged 16-25 with lived experience of ADHD (or a parent/carer), a health professional, or commissioner/provider of health services
- Not currently resident or working in England
- Not currently resident, working, or studying close to one of the qualitative study sites identified following WP1, where 'close to' means located within the same geographic locality (to be decided based on findings from WP1)
Show all 10Show fewer
- WP3 Co-PRODUCTION
- Not a young person aged 16-25 with lived experience of ADHD (or a parent/carer), a health professional, commissioner/provider of NHS health services, or a member of the MAP study research team
- Not currently resident, working, or studying in England
- Not willing and able to work collaboratively and engage in consultations to co-produce evidence-based guidance for improving the co-ordination of primary care for young people with ADHD
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Managing Young People With Attention Deficit Hyperactivity Disorder in Primary Care (MAP) Study: Mapping Current Practice and Co-producing Guidance to Improve Healthcare in an Underserved Population
Background:
Attention deficit hyperactivity disorder (ADHD) is the most common childhood neurodevelopmental disorder. It affects around 5% of children and adolescents, and up to 40% continue to experience symptoms into adulthood. Primary care practitioners (e.g., general practitioners (GPs), nurses, link workers, clinical pharmacists) play an important role in the healthcare of young people (YP) with ADHD, particularly due to long waiting times in adult mental health services, and patchy provision of specialist services. However, many practitioners feel unsure about how to support YP at this vulnerable stage in their lives. Practitioners report concerns about prescribing ADHD medication and a desire for more guidance. Currently, little is known about how YP with ADHD are supported in primary care, the strengths and weakness of existing care pathways, and how care can be improved.
Read more
Aims:
To provide an evidence-base by mapping current services, and co-produce guidance to improve and better co-ordinate primary care for YP aged 16-25 with ADHD.
Methods:
Three interlinked studies. A mapping study including a national survey of stakeholders to map patient pathways, prescribing practice, shared-care arrangements, and practitioner roles. A qualitative study including semi-structured interviews with YP and practitioners, to gain insight into experiences of 'what works' and 'what is needed'. Workshops to co-develop a map of patient pathways, key messages, and clinical guidance.
Patient Involvement:
This research has been developed in response to identified gaps in services, and requests from people with ADHD. The team includes young people with ADHD whose input will help ensure the research is sensitive and relevant, and an academic GP to ensure identified solutions are deliverable within primary care settings.
Impact:
The expected impact of this research is improvement of the quality and experience of care for YP with ADHD. Also, to improve experiences of primary care providers facing difficulties managing ADHD.
Read the detailed description
This research aims to map current services and co-create evidence-based guidance to improve and better co-ordinate primary care for young people aged 16-25 years with ADHD.
OBJECTIVES
The objectives of this research are to:
- Develop a national map and overview of current primary care pathways and prescribing practice in the management of young people with ADHD
- Explore:
- Primary care providers and related organisations' needs for information resources and prescribing support in their roles managing care for young people with ADHD
- The expectations and needs of young people aged 16-25 regarding primary care ADHD support, information, and management
- Co-produce evidence informed guidance to better co-ordinate primary care for young people with ADHD, based on discussions around findings from objectives 1, 2a and 2b
OUTCOMES
The outcomes of this research will be shaped by close work with professionals and members of the community, via the practice and policy research advisory group (P-RAG) and young person and parent/carer research advisory group (Y-RAG) groups, to ensure their relevance and utility. Anticipated outcomes include:
- National overview of primary care provision for young people with ADHD across England, including:
- Geographic map, showing variation in provision by NHS region or appropriate organisational boundaries
- Summary of existing care pathways for the management of young people with ADHD in primary care, including exemplars of best practice
- Qualitative summary of the perspectives of people involved in delivering and in need of care, on the management of ADHD in primary care including:
- Health professionals' needs for information resources and prescribing support
- Young people with ADHD and their parent/carers' needs for information resources, healthcare, and support with self-management
- Co-produced guidance on how to better co-ordinate and design primary care for young people aged 16-25 with ADHD.
STUDY DESIGN and METHODS Overview: This mixed methods study consists of three work packages. Each WP involves data collection/creation working with the following stakeholder groups.
- Patients, with a focus on young people (aged 16-25) with ADHD, and their parent/carers
- Health professionals, with a focus on those in primary care (including general practitioners (GPs), specialist nurses, mental health practitioners, and clinical pharmacists)
- Commissioners/providers of NHS healthcare for people with ADHD
- Conditions
- ADHD
- Being tested
- None, observational study
- Keywords
- Young adult, Service provision
- Medical subject headings
- Attention Deficit Disorder with Hyperactivity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
None, observational studyOther
The MAP study involves mapping current practice (WP1), exploring current experiences (WP2), and co-creating guidance based on existing evidence (WP3).
| Study group | Role | What they receive |
|---|---|---|
| Work package 1 (WP1) - survey | WP1 aims to recruit a minimum of 252 survey respondents, providing a minimum of six responses for each of the 42 Integrated Care Systems (ICSs) in England. The aim will be to gather responses from as many respondents as possible, to provide as much information as possible on primary care provision across over >1200 PCNs in England. This will provide the first national overview of prescribing practice and the availability of health care for young people with ADHD through primary care in England. The inclusion of three stakeholder groups (health professional, service users, and commissioners/providers) will ensure that the survey includes reports from a balance of perspectives and provide the opportunity to compare data between groups and locations.
The sampling frame for WP1 includes all stakeholders aged 16 or over with an interest in providing or receiving health care for young people with ADHD, as well as those involved in providing/commissioning local primary care provision. Receives: Other: None, observational study | |
| Work package 2 (WP2) - qualitative study | WP2 aims to recruit between 20 and 30 participants, consisting of 10-15 young people (aged 16-25) with ADHD and their parent carers and 10-15 health professionals and commissioners/providers. Participants will be recruited from between three and six geographic locations (e.g., PCNs), dependent on findings from WP1. This sample size will enable qualitative data to be collected from approximately five participants per location.
The sampling frame for WP2 consists of a purposive selection of stakeholders. Receives: Other: None, observational study | |
| Work package 3 (WP3) - co-production of guidance | WP3 aims to recruit between six and 16 participants, consisting of 2-6 young people (aged 16-25) with ADHD and/or their parents/carers, 2-6 health professional and/or commissioners/providers, and between 1 and 4 members of the research team. The sample will be sufficient to include perspectives from identified key stakeholders, while the relatively small group size will support close group work. The small sample size will also enable delivery of key features of co-production research such as building strong relationships and providing opportunities for growth and development of participants.
The sampling frame for WP3 consists of a purposive selection of key stakeholders. In addition to the key stakeholder groups outlined above, co-production activities will also involve MAP study researchers. Receives: Other: None, observational study |
What is being measured
The primary outcome is the main question the study is designed to answer.
WP1: Reports of the prescribing of adult ADHD medication, by primary care practices in England
WP1 (national survey) will report on prescribing of ADHD medication by primary care practices in England. Outcome data will be communicated as a summary total of 'yes' / 'no' survey responses, and analysed by the geographic location of practices, as well as the type of respondent reporting this practice (e.g., person with ADHD, clinician, or commissioner)
Measured: At time of completing survey
Secondary outcomes (3)
WP1: Reports of shared care agreements being in place for prescribing of adult ADHD medication, by local primary care practices (in England)
WP1 (national survey) will report on the presence of shared care agreements for prescribing of ADHD medication by primary care practices in England. Outcome data will be communicated as a summary total of 'yes' / 'no' survey responses, and analysed by the geographic location of practices, as well as the type of respondent reporting this practice (e.g., person with ADHD, clinician, or commissioner)
Measured: At time of completing survey
WP1: Reports of mental health support being in place for patients with adult ADHD medication, by local primary care practices (in England)
WP1 (national survey) will report on the presence of shared care agreements for prescribing of ADHD medication by primary care practices in England. Outcome data will be communicated as a summary total of 'yes' / 'no' survey responses, and analysed by the geographic location of practices, as well as the type of respondent reporting this practice (e.g., person with ADHD, clinician, or commissioner)
Measured: At time of completing survey
WP2: Qualitative summary of the perspectives of people involved in delivering and in need of care, on the management of ADHD in primary care medication, by local primary care practices (in England)
WP2 (qualitative study) will report on experiences of primary care provision for young people with ADHD across England, from the perspectives of health professionals and young people with ADHD. Topics covered will include, prescribing practice, shared care agreements, and information provision.
Measured: At time of interview
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Aug 2022
- Study start28 Sep 2022
- Primary completion31 Mar 2024
- Study completion31 Mar 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for ADHDStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Ecologic or community
- Time perspective
- Cross-sectional
- Enrolment
- 816 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Exeter
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Anna Price, PhD, Principal investigator, University of Exeter Medical School
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05518435
- Sponsor's protocol ID
- 313424
- Other IDs
- MHF008
- Acronym
- MAP
- Status last verified
- May 2024
- First submitted
- 24 Aug 2022
- Last updated
- 8 May 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Arrangements for access to the final study dataset are outlined in the MAP study data management plan. In summary: * Only members of the study research team will have access to the full dataset. * It is possible that anonymised data from this dataset may be used for secondary analysis. This possibility is detailed in the study Participant Information Sheet (PIS) and Consent forms and would therefore only take place with the consent of the participants. All patient documentation reflects the possible future use an anonymised subset of these data in research.
Publications
Price A, Smith JR, Mughal F, Salimi A, Melendez-Torres GJ, Newlove-Delgado T. Protocol for the mixed methods, Managing young people (aged 16-25) with Attention deficit hyperactivity disorder in Primary care (MAP) study: mapping current practice and co-producing guidance to improve healthcare in an underserved population. BMJ Open. 2023 Jul 10;13(7):e068184. doi: 10.1136/bmjopen-2022-068184.
PubMed 37429692
Study at a glance
From the registry record, last updated by the sponsor on 8 May 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Managing Young People With Attention Deficit Hyperactivity Disorder in Primary Care (MAP) Study: Mapping Current Practice and Co-producing Guidance to Improve Healthcare in an Underserved Population
- ClinicalTrials.gov ID
- NCT05518435
- Acronym / sponsor ID
- MAP / 313424
- Conditions
- ADHD
- Keywords
- Young adult, Service provision
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 816 participants (actual)
- Lead sponsor
- University of ExeterUniversity, hospital or other
- Study start
- 28 Sep 2022 (actual)
- Primary completion
- 31 Mar 2024 (actual)
- Study completion
- 31 Mar 2024 (actual)
- First posted
- 26 Aug 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background:
Attention deficit hyperactivity disorder (ADHD) is the most common childhood neurodevelopmental disorder. It affects around 5% of children and adolescents, and up to 40% continue to experience symptoms into adulthood. Primary care practitioners (e.g., general practitioners (GPs), nurses, link workers, clinical pharmacists) play an important role in the healthcare of young people (YP) with ADHD, particularly due to long waiting times in adult mental health services, and patchy provision of specialist services. However, many practitioners feel unsure about how to support YP at this vulnerable stage in their lives. Practitioners report concerns about prescribing ADHD medication and a desire for more guidance. Currently, little is known about how YP with ADHD are supported in primary care, the strengths and weakness of existing care pathways, and how care can be improved.
Aims:
To provide an evidence-base by mapping current services, and co-produce guidance to improve and better co-ordinate primary care for YP aged 16-25 with ADHD.
Methods:
Three interlinked studies. A mapping study including a national survey of stakeholders to map patient pathways, prescribing practice, shared-care arrangements, and practitioner roles. A qualitative study including semi-structured interviews with YP and practitioners, to gain insight into experiences of 'what works' and 'what is needed'. Workshops to co-develop a map of patient pathways, key messages, and clinical guidance.
Patient Involvement:
This research has been developed in response to identified gaps in services, and requests from people with ADHD. The team includes young people with ADHD whose input will help ensure the research is sensitive and relevant, and an academic GP to ensure identified solutions are deliverable within primary care settings.
Impact:
The expected impact of this research is improvement of the quality and experience of care for YP with ADHD. Also, to improve experiences of primary care providers facing difficulties managing ADHD.
Detailed description
This research aims to map current services and co-create evidence-based guidance to improve and better co-ordinate primary care for young people aged 16-25 years with ADHD.
OBJECTIVES
The objectives of this research are to:
- Develop a national map and overview of current primary care pathways and prescribing practice in the management of young people with ADHD
- Explore:
- Primary care providers and related organisations' needs for information resources and prescribing support in their roles managing care for young people with ADHD
- The expectations and needs of young people aged 16-25 regarding primary care ADHD support, information, and management
- Co-produce evidence informed guidance to better co-ordinate primary care for young people with ADHD, based on discussions around findings from objectives 1, 2a and 2b
OUTCOMES
The outcomes of this research will be shaped by close work with professionals and members of the community, via the practice and policy research advisory group (P-RAG) and young person and parent/carer research advisory group (Y-RAG) groups, to ensure their relevance and utility. Anticipated outcomes include:
- National overview of primary care provision for young people with ADHD across England, including:
- Geographic map, showing variation in provision by NHS region or appropriate organisational boundaries
- Summary of existing care pathways for the management of young people with ADHD in primary care, including exemplars of best practice
- Qualitative summary of the perspectives of people involved in delivering and in need of care, on the management of ADHD in primary care including:
- Health professionals' needs for information resources and prescribing support
- Young people with ADHD and their parent/carers' needs for information resources, healthcare, and support with self-management
- Co-produced guidance on how to better co-ordinate and design primary care for young people aged 16-25 with ADHD.
STUDY DESIGN and METHODS Overview: This mixed methods study consists of three work packages. Each WP involves data collection/creation working with the following stakeholder groups.
- Patients, with a focus on young people (aged 16-25) with ADHD, and their parent/carers
- Health professionals, with a focus on those in primary care (including general practitioners (GPs), specialist nurses, mental health practitioners, and clinical pharmacists)
- Commissioners/providers of NHS healthcare for people with ADHD
Study design
- Observational model
- Ecologic or community
- Time perspective
- Cross-sectional
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Work package 1 (WP1) - survey | – | Other: None, observational studyWP1 aims to recruit a minimum of 252 survey respondents, providing a minimum of six responses for each of the 42 Integrated Care Systems (ICSs) in England. The aim will be to gather responses from as many respondents as possible, to provide as much information as possible on primary care provision across over >1200 PCNs in England. This will provide the first national overview of prescribing practice and the availability of health care for young people with ADHD through primary care in England. The inclusion of three stakeholder groups (health professional, service users, and commissioners/providers) will ensure that the survey includes reports from a balance of perspectives and provide the opportunity to compare data between groups and locations. The sampling frame for WP1 includes all stakeholders aged 16 or over with an interest in providing or receiving health care for young people with ADHD, as well as those involved in providing/commissioning local primary care provision. |
| Work package 2 (WP2) - qualitative study | – | Other: None, observational studyWP2 aims to recruit between 20 and 30 participants, consisting of 10-15 young people (aged 16-25) with ADHD and their parent carers and 10-15 health professionals and commissioners/providers. Participants will be recruited from between three and six geographic locations (e.g., PCNs), dependent on findings from WP1. This sample size will enable qualitative data to be collected from approximately five participants per location. The sampling frame for WP2 consists of a purposive selection of stakeholders. |
| Work package 3 (WP3) - co-production of guidance | – | Other: None, observational studyWP3 aims to recruit between six and 16 participants, consisting of 2-6 young people (aged 16-25) with ADHD and/or their parents/carers, 2-6 health professional and/or commissioners/providers, and between 1 and 4 members of the research team. The sample will be sufficient to include perspectives from identified key stakeholders, while the relatively small group size will support close group work. The small sample size will also enable delivery of key features of co-production research such as building strong relationships and providing opportunities for growth and development of participants. The sampling frame for WP3 consists of a purposive selection of key stakeholders. In addition to the key stakeholder groups outlined above, co-production activities will also involve MAP study researchers. |
Who may qualify
- Ages
- 16 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- WP1 SURVEY The sampling frame for WP1 includes all stakeholders aged 16 or over with an interest in providing or receiving health care for young people with ADHD, as well as those involved in providing/commissioning local primary care provision. WP2 QUALITATIVE STUDY The sampling frame for WP2 consists of a purposive selection of stakeholders. WP3 CO-PRODUCTION The sampling frame for WP3 consists of a purposive selection of key stakeholders. In addition to the key stakeholder groups outlined above, co-production activities will also involve MAP study researchers.
Key inclusion criteria (19 listed)
- Self-identifies as
- Being at least one of the following:
- Currently resident, working, or studying in England
- One of the following:
- Currently resident or working in England
Key exclusion criteria (10 listed)
- Does not identify as a person aged 16 or over with lived experience of ADHD, a health professional, or a commissioner/provider of NHS health services
- Not currently resident, working, or studying in England
- WP2 QUALITATIVE STUDY
- Not a young person aged 16-25 with lived experience of ADHD (or a parent/carer), a health professional, or commissioner/provider of health services
- Not currently resident or working in England
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| None, observational studyThe MAP study involves mapping current practice (WP1), exploring current experiences (WP2), and co-creating guidance based on existing evidence (WP3). | Other | Work package 1 (WP1) - survey, Work package 2 (WP2) - qualitative study, Work package 3 (WP3) - co-production of guidance |
Primary outcome
WP1: Reports of the prescribing of adult ADHD medication, by primary care practices in England
Time frame: At time of completing survey
WP1 (national survey) will report on prescribing of ADHD medication by primary care practices in England. Outcome data will be communicated as a summary total of 'yes' / 'no' survey responses, and analysed by the geographic location of practices, as well as the type of respondent reporting this practice (e.g., person with ADHD, clinician, or commissioner)
3 secondary outcomes
WP1: Reports of shared care agreements being in place for prescribing of adult ADHD medication, by local primary care practices (in England)
Time frame: At time of completing survey
WP1: Reports of mental health support being in place for patients with adult ADHD medication, by local primary care practices (in England)
Time frame: At time of completing survey
WP2: Qualitative summary of the perspectives of people involved in delivering and in need of care, on the management of ADHD in primary care medication, by local primary care practices (in England)
Time frame: At time of interview
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 May 2024.
- Derived from this study: PubMed 37429692Price A, Smith JR, Mughal F, Salimi A, Melendez-Torres GJ, Newlove-Delgado T. Protocol for the mixed methods, Managing young people (aged 16-25) with Attention deficit hyperactivity disorder in Primary care (MAP) study: mapping current practice and co-producing guidance to improve healthcare in an underserved population. BMJ Open. 2023 Jul 10;13(7):e068184. doi: 10.1136/bmjopen-2022-068184.
- Study website, with additional background information. Public facing, and hosted by Sponsor organisation (University of Exeter)Link provided by the sponsor.
- Individual participant dataSharing planned: No. Arrangements for access to the final study dataset are outlined in the MAP study data management plan. In summary: * Only members of the study research team will have access to the full dataset. * It is possible that anonymised data from this dataset may be used for secondary analysis. This possibility is detailed in the study Participant Information Sheet (PIS) and Consent forms and would therefore only take place with the consent of the participants. All patient documentation reflects the possible future use an anonymised subset of these data in research.
Related trials for ADHD
RecruitingObservational study
Psychotherapy for Irritability in Youth: Comparing Active Treatment to Nonactive Psychoeducation Supportive Psychotherapy
Irritability, Disruptive Mood Dysregulation Disorder
RecruitingObservational study
Augmenting Parent Management Training for Child Temper Outbursts Using a Digital Tool
Disruptive Behavior Disorders, Conduct Disorder
RecruitingPhase 2
A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)
Attention Deficit Disorder With Hyperactivity (ADHD)
Not yet recruiting
QAIAx - SGI/SI Smart Health Cities: Microcity Enclave Program (Quantum SI/AGI Agency a/k/a AI City Hall Project - UPSTO App Nos. 64/074,526, 64/063,557, 64/105,164, 63/903,181, 63/729,428, 64/125,360; USPTO EO 9424 Assignment ID: 2101042 / ARN: REEL/FRAME: 76481/0026 - OUSD-R&E, Department of War)
Asperger's Disorder, Asperger Disorder
RecruitingObservational study
Pharmacogenomics of Stimulant Treatment Response
Attention-Deficit/ Hyperactivity Disorder (ADHD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Anna Price, PhD principal investigator
University of Exeter Medical School
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of ADHD, run by University of Exeter at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 19 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 May 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
WP1: Reports of the prescribing of adult ADHD medication, by primary care practices in England (time frame: At time of completing survey). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05518435, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 May 2024.